Rhythm Pharmaceuticals financials
$95.71−2.89%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M | — | — | — | — |
| Gross profit | $170.3M | $116.8M | $68.1M | $21.5M | $2.6M | — | — | — | — |
| Gross margin | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | — | — | — | — |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M | -$136.6M | -$146.0M | -$78.4M | -$32.4M |
| Net income | -$201.9M | -$264.6M | -$184.7M | -$181.1M | -$69.6M | -$134.0M | -$140.7M | -$74.1M | -$37.6M |
| Net margin | −106.4% | −203.3% | −238.5% | −766.2% | −2207.1% | — | — | — | — |
| Diluted EPS | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | $-2.39 | $-2.83 |
| EBITDA | -$190.7M | -$263.9M | -$182.6M | -$179.2M | -$170.1M | -$135.9M | -$146.0M | -$78.0M | -$32.2M |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M | -$122.0M | -$122.8M | -$62.1M | -$29.5M |
| Free cash flow | -$116.6M | -$113.9M | -$136.2M | -$173.7M | -$146.4M | -$122.2M | -$126.1M | -$62.8M | -$29.6M |
| Diluted shares | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M | 44.1M | 36.4M | 31.0M | 13.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.3M | $89.1M | $60.1M | $127.7M | $59.2M | $100.9M |
| Short-term investments | $334.6M | $231.4M | $215.8M | $205.6M | $235.6M | $71.9M |
| Total debt | $108.2M | $109.8M | $106.1M | $0.00 | $0.00 | $0.00 |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M | $187.1M |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M | $20.5M |
| Shareholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M | $166.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology